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ORIGINAL INVESTIGATION
Long-term effects of the 
multidisciplinary risk assessment 
and management program for patients 
with diabetes mellitus (RAMP-DM): a 
population-based cohort study
Fangfang Jiao1*, Colman Siu Cheung Fung1, Yuk Fai Wan1, Sarah Morag McGhee2, Carlos King Ho Wong1, 
Daisy Dai3, Ruby Kwok3 and Cindy Lo Kuen Lam1
Abstract 
Background: Studies on the long-term effectiveness of multidisciplinary risk-stratification based management in 
Chinese population were rare. This study aimed to evaluate the effectiveness of a multidisciplinary risk assessment 
and management program for patients with diabetes mellitus (RAMP-DM) in reducing the risks of cardiovascular 
complications and all-cause mortality.
Methods: A prospective cohort study was conducted in 18,188 propensity score matched RAMP-DM participants 
and subjects with diabetes under usual primary care (9,094 subjects in each group). The study endpoints were the first 
occurrence of coronary heart disease (CHD), stroke, heart failure (HF), total cardiovascular disease (CVD) and all-cause 
mortality. We constructed multivariable Cox proportional hazard regressions to estimate the association between the 
RAMP-DM intervention and the first occurrence of study endpoints.
Results: The median follow-up period was 36 months. Three hundred and ninety-nine CVD events occurred in the 
RAMP-DM group, as compared with 608 in the control group [adjusted hazard ratio, 0.629; 95 % confidence interval 
(CI) 0.554–0.715; P < 0.001]. The total number of all-cause deaths in RAMP-DM group was less than half that of control 
group (202 vs 552, adjusted hazard ratio, 0.363; 95 % CI, 0.308–0.428; P < 0.001). The adjusted hazard ratios of the 
RAMP-DM group for CHD, stroke, and HF were 0.570 (95 % CI, 0.470–0.691; P < 0.001), 0.652 (95 % CI, 0.546–0.780; 
P < 0.001), and 0.598 (95 %CI, 0.446–0.802; P = 0.001), respectively.
Conclusions: The RAMP-DM intervention was associated with lower incidences of individual and total cardiovascular 
complications, as well as all-cause mortality over 3 years follow-up. The encouraging results provided evidence to sup-
port that the structured risk-stratification management leading by a multidisciplinary clinical team was an effective 
approach to reduce future cardiovascular complications in people with diabetes.
Clinical trial registry: NCT02034695, http://www.ClinicalTrials.gov
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Background
The increasing prevalence of diabetes mellitus (DM) 
posts one of the most challenging health problems world-
wide. According to the estimates from the International 
Diabetes Federation, the number of people with DM is 
projected to reach 592 million by 2035, a 50 % increase 
compared to 382 million in 2013 [1]. In China, there are 
more than 98 million people with DM currently, account-
ing for about a quarter of the total people with DM in 
the world [2]. In Hong Kong, one of the most developed 
regions of China, the prevalence of DM is higher than 
the reported national average, reaching nearly 10  % [2, 
3]. Diabetes has been implicated as the underlying cause 
of 36 % of all-cause mortality [2] and a leading cause of 
coronary heart disease and stroke [4]. The annual direct 
medical cost of diagnosed DM in Hong Kong was esti-
mated to take up 6.4 % of public health care expenditure 
with the management of diabetes-related complications a 
major driver of the cost [5].
Although DM increases the risk of cardiovascular dis-
ease by 2-5 times [6, 7], the risks of developing diabetic 
cardiovascular complications vary widely among indi-
viduals. Risk prediction algorithms have been developed 
for cardiovascular complications [8]. Given the increas-
ing number of subjects with DM and the rising disease 
burden, risk stratification-based management is appeal-
ing to avoid complications among high risk cases and 
allocate limited healthcare resources efficiently. In recent 
years, guidelines have recommended risk stratification 
based management [9–11], setting personalized treat-
ment goals based on patients’ individual cardiovascular 
risks. Personalized management is advocated as a means 
of translating the evidence from randomized control tri-
als to real-world settings [12]. However, there is a lack of 
studies on the effectiveness of risk stratification-based 
personalized management [12].
To implement risk-stratification based management, a 
multidisciplinary team is required, including nurses, doc-
tors and allied health professionals. The Chronic Care 
Model advocated by Wagner et  al. serves as the con-
ceptual framework for many multidisciplinary diabetes 
management interventions in primary care [13]. Accu-
mulating evidence shows that multidisciplinary inter-
ventions can improve blood glucose control [14–17] and 
reduce complications in patients with diabetes [18].
To enhance the management of diabetic subjects in 
primary care setting in Hong Kong, a multidisciplinary 
risk assessment and management program for patients 
with diabetes mellitus (RAMP-DM) has been operat-
ing in public general out-patient clinics (GOPCs) since 
August 2009. The details of the intervention and effec-
tiveness of the program at 12 months have been reported 
[19, 20]. It was found that, compared to the DM subjects 
under usual care, the RAMP-DM group had significant 
improvement in their HbA1c levels and predicted cardio-
vascular risks at 12-months of follow-up [20].
There was a lack of evidence on the long-term effec-
tiveness of multidisciplinary risk-stratification based 
management programs in Chinese population. This study 
aimed at evaluating the impact of RAMP-DM on the 
incidences of diabetic cardiovascular complications and 
all-cause mortality at 3 years of follow-up. It was hypoth-
esized that RAMP-DM participants would have lower 
risks of developing the cardiovascular complications and 
all-cause mortality compared to usual primary care.
Methods
Study design
We conducted a prospective cohort study to compare the 
risks of developing cardiovascular complications and all-
cause mortality over 3 years between people with diabe-
tes managed under RAMP-DM and those receiving usual 
primary care.
Setting of RAMP‑DM
The Hong Kong Hospital Authority, the sole public 
healthcare provider in Hong Kong, launched the RAMP-
DM in August 2009 as a territory-wide primary care 
service component for people with diabetes in public 
General Out-patient Clinics (GOPCs). The details of 
the RAMP-DM program have been reported previously 
[19]. In brief, the enrolled subjects underwent a compre-
hensive risk factor screening for diabetes-related com-
plications. Trained Registered Nurses conducted the 
Nurse Intake Assessment, during which they assessed 
the screening results and stratified patients into ‘very 
high’, ‘high’, ‘medium’ and ‘low’ risk groups according to 
the JADE classification [21]. Then the RAMP-DM sub-
jects were assigned to receive appropriate interventions 
and education provided by a team of multi-disciplinary 
healthcare professionals, including Associate Consult-
ants in family medicine, Registered Nurses, Advanced 
Practice Nurses and allied health professionals (optome-
trist, dietitian, podiatrist, physiotherapist, etc.) according 
to their stratified risk level and HbA1c level (Additional 
file 1: Figure S1). According to patients’ risk levels, some 
RAMP-DM subjects have annual full risk factors screen-
ing and Nurse Intake Assessment, and others have the 
full assessment every 2–3  years with annual blood test 
and followed-up by their GOPC doctors.
Subjects under usual primary care continued to be 
managed by their GOPC doctors without risk assessment 
and stratification. They were also eligible for referral to 
allied health professionals at their doctors’ discretion.
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Subjects
The RAMP-DM aimed at covering all people with DM. 
The inclusion criterion for RAMP-DM is: all subjects 
with diabetes who are followed up regularly at GOPCs. 
Up to 31st July 2013, the end date of our study data col-
lection period, there were 147,097 enrolled into RAMP-
DM (out of a total of 206,238 patients receiving diabetic 
care under the primary care service of HA from August 
2008 to July 2013). The remaining people with diabetes 
were continued to be enrolled into RAMP-DM after 31st 
July 2013, and they served as potential control subjects in 
this study.
Subjects for this study were identified from the Clinical 
Management System database of the Hospital Author-
ity. Inclusion criteria for this study are, (1) Age ≥18; (2) 
Patients with documented International Classification 
of Primary Care (ICPC-2) codes T89/T90 before base-
line dates; (3) Patients with at least one public primary 
clinics attendance before baseline dates. To evaluate the 
effectiveness of RAMP-DM in reducing primary diabe-
tes-related complications, we excluded subjects with any 
pre-existing diabetes-related complications. To reduce 
potential bias in mortality rates, we further excluded 
subjects diagnosed with cancer, chronic lung disease and 
psychological conditions at baseline.
The RAMP-DM cohort comprised subjects with diabe-
tes who were enrolled in RAMP-DM between 1st August 
2009 and 31st July 2010. The control group cohort was 
diabetic subjects who attended GOPC on or before 31st 
January 2010, and was not enrolled in RAMP-DM by 31st 
July, 2013. The baseline dates for the RAMP-DM group 
were their first risk assessment dates. To reduce poten-
tial lead-time bias, we set 31st January 2010, the middle 
date of the baseline dates among RAMP-DM subjects, as 
the baseline date for the control group. All subjects were 
observed until a study endpoint or 3  years since their 
baseline date using the date of their last follow-up as a 
censor date.
Ethical approval of this study was granted by the Insti-
tutional Review Board of the University of Hong Kong/
Hospital Authority: Hong Kong West Cluster (UW 
10-369), New Territories East Cluster (CRE-2010.543), 
New Territories West Cluster (NTWC/CREC/1091/12), 
Kowloon East and Kowloon Central Cluster (KC/KE-10-
0210/ER-3), Kowloon West Cluster (KW/EX/10-317 (34–
04)), and Hong Kong East Cluster (HKEC-2010-093).
Propensity score matching
To reduce any selection bias, we matched the subjects 
in the RAMP-DM and control groups using propensity 
score matching. This technique pairs individuals based 
on observable characteristics which indicate a similar 
probability of receiving treatment (similar propensity 
score), but one of them received the intervention and 
the other did not. The propensity score is the condi-
tional probability of receiving the intervention given 
the observed baseline covariates and it is independent 
of the outcomes. Propensity score matching is appro-
priate for studies with a large sample size and many 
covariates [22]. We generated a propensity score for 
each patient, and modelled the RAMP-DM interven-
tion as the dependent variable with the baseline covar-
iates as the independent variables. The propensity 
score matching was conducted using the “psmatch2” 
STATA package by one-to-one matching without 
replacement and with a caliper of 0.001, which means 
the differences of propensity scores for each matched 
pair was within 0.001. The unmatched control subjects 
were discarded.
The baseline covariates for developing the propensity 
score were (1) demographic characteristics, including 
age, sex, whether on comprehensive social security assis-
tance; (2) clinical parameters, including smoking status, 
duration of diabetes, HbA1c, low-density lipoprotein 
cholesterol (LDL-C), total cholesterol (TC), high-density 
lipoprotein cholesterol (HDL-C), triglyceride systolic 
blood pressure (SBP), diastolic blood pressure (DBP), 
body mass index (BMI), and estimated glomerular filtra-
tion rate; (3) treatment modality, including oral glucose-
lowering drugs, anti-hypertensive drugs, lipid-lowering 
drugs and insulin; and (4) comorbidities, measured by 
the Charlson comorbidity score [23].
Study endpoints
The endpoint for this study was the time to first occur-
rence of a major diabetes-related complication including 
(1) coronary heart disease (CHD), (2) stroke, (3) heart 
failure (HF), (4) a composite of the former three cardio-
vascular diseases (CVD) and (5) death from any cause. 
The incidence of diabetes-related complications was 
identified by the International Classification of Diseases, 
Ninth Edition, Clinical Modification and ICPC-2 codes 
from the Clinical Management System of the Hospital 
Authority (Table 1). The death cases were identified from 
death registration data.
Data analysis
We used the independent t test or Chi squared test, as 
appropriate, to compare the demographic and clinical 
parameters between the RAMP-DM and control groups 
at baseline and the end of follow-up. The cumulative 
incidence rates for each type of diabetic complication 
and all-cause mortality are reported. We constructed the 
95  % confidence intervals of the incidence rates based 
on the assumption that the observed incident events fol-
lowed a Poisson distribution.
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For each of the study endpoints, the Kaplan–Meier 
method was used to estimate the survival curves and the 
log-rank test was used to compare the between group 
differences. To estimate the magnitude of differences 
in endpoints, multivariable Cox proportional hazards 
regression models were employed to explore the effects 
of RAMP-DM on the dependent variables of each end-
point, adjusting for all the baseline covariates. The hazard 
ratio (HR) with 95  % confidence interval were reported 
for each of the endpoints. The predictive accuracy of each 
regression model was evaluated using Harrell’s discrimi-
nation C-index, ranging from 0 to 1. A value of 0.5 indi-
cates the model does not have predictive discrimination 
ability, and values of 0 or 1 indicate perfect ability to dis-
criminate subjects [24]. As the interventions in RAMP-
DM groups were stratified by subjects’ HbA1c levels, we 
further explored the effects of RAMP-DM in preventing 
diabetic complications in three subgroups, i.e. HbA1c 
<7  % (53  mmol/mol), 7  %≤  HbA1c  <8.5  % (69  mmol/
mol), and HbA1c ≥8.5 %.
Intention to treat analysis was adopted.
We performed all the statistical analyses using STATA 
Version 13.0 (StataCorp LP. College Station, Texus, US), 
and P value less than 0.05 was considered as statistically 
significant.
Results
Baseline characteristics
From 1st Aug 2009 to 31st July 2010, a total of 18,459 
diabetic subjects under primary care were enrolled in 
RAMP-DM (Fig. 1). We identified 47,148 potential con-
trol subjects met the inclusion criteria for the study. Sub-
jects with any existing diabetes-related complications 
were excluded in each group, giving 16,289 and 38,669 
subjects in RAMP-DM and control groups respectively. 
Limiting the eligibility to subjects without prior diagnosis 
of cancer, chronic lung disease and psychological condi-
tions in both groups reduced the sample to 14,377 and 
32,562 in RAMP-DM and control groups respectively. 
We further excluded 22,500 cases (253 in RAMP group 
and 22,247 in control group) with incomplete baseline 
data, leaving 14,124 RAMP-DM subjects and 10,315 con-
trol subject. To reduce selection bias, we further refined 
the study sample using propensity score matching. The 
final matched sample for this study comprised 9,094 
RAMP-DM subjects and 9,094 control subjects.
The comparison of baseline characteristics between 
the two groups is shown in Table  2. At baseline, all the 
demographic, clinical parameters and treatment modal-
ity of the patients were not significantly different between 
the two groups. The average age of the two cohorts was 
64, and around 87 % subjects were on oral glucose-low-
ering drugs. At the end of follow-up, the RAMP-DM sub-
jects showed significantly lower HbA1c (7.13 vs 7.25  %, 
P < 0.001) and SBP (130.12 vs 132.35 mm Hg, P < 0.001). 
Regarding the treatment modalities, the RAMP-DM 
group showed higher percentages of patients on all the 
four types of drugs (glucose-lowering drugs, anti-hyper-
tensive drugs, lipid-lowering drugs and insulin) than the 
control group.
Observed incidence of diabetes‑related complications 
and all‑cause mortality
Table 3 shows the observed number of the first diagno-
ses of each type of diabetes-related complication and 
the incidence rates over a median follow-up period of 
36  months among 9,094 subjects in each group. More 
than 25,000 person-years of observation were avail-
able for each of the study endpoints in both groups. The 
RAMP-DM group had lower incidence rates for all the 
primary and secondary endpoints with 399 and 608 CVD 
events in the RAMP-DM and control groups respectively. 
Stroke was the most prevalent CVD in both groups (205 
and 309 stroke events in RAMP-DM and control group, 
respectively). Over the observation period, 552 death 
cases occurred in the control group, which was more 
than twice that in the RAMP-DM group (202 cases).
The Kaplan–Meier survival curves for each study end 
point are shown in Fig. 2. For all the cardiovascular com-
plications and all-cause mortality, the RAMP-DM group 
showed lower incidence rates from the beginning of the 
observation period and the differences became larger 
over the follow-up period. The log-rank test showed the 
RAMP-DM group had significantly lower risks of all the 
studied complications and all-cause mortality than the 
control group.
Table 1 ICD-9CM, ICPC-2 codes for diabetic macrovascular complications
ICD-9-CM International classification of diseases, ninth edition, clinical modification; ICPC-2 international classification of primary care.
Disease ICPC‑2 codes ICD‑9‑CM codes
Coronary heart disease (CHD) K74–K76 410.00–410.92; 411.0–411.89; 412; 413.0–413.9; 414.0–414.9; 798.1–798.9
Heart failure K77 428.0–428.9
Stroke K89–K91 430; 431; 432.0–432.9; 433.00–433.91; 434.00–434.91; 435.0–435.9; 436; 437.0–437.9; 438.0–438.9
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Multivariable Cox regression models
We constructed multivariable Cox regression models to 
evaluate the hazard ratios (HR) between RAMP-DM and 
control groups for each study endpoint adjusted for all 
the baseline covariates. As shown in Table  4, compared 
to the control group, the RAMP-DM group significantly 
reduced the incidence of total CVD (HR: 0.629, 95 % CI 
0.554–0.715, P  <  0.001) and also had significant lower 
risks of developing CHD (HR: 0.570, 95  % CI 0.470–
0.691, P < 0.001), stroke (HR: 0.652, 95 % CI 0.546–0.780, 
P < 0.001) and heart failure (HR: 0.598, 95 % CI 0.446–
0.802, P  =  0.001). The all-cause mortality was signifi-
cantly lower in the RAMP-DM group (HR: 0.363, 95 % CI 
0.308–0.428, P < 0.001).
Sub‑group analysis
The results of sub-group analysis are shown in Table  4. 
We found that the RAMP-DM group had significantly 
lower risks of developing CHD, total CVD and of all-
cause mortality in all three sub-groups. The decrease 
in total CVD risk in the RAMP-DM group in the 
7 %≤ HbA1c <8.5 % group was lower than the other two 
sub-groups (HbA1c <7  % and HbA1c ≥8.5  %), whereas 
the risk of heart failure decreased most in this group.
Discussion
To the best of our knowledge, this is the first study 
exploring the long-term effects of a multidisciplinary 
risk-stratified management program in reducing diabetic 
cardiovascular complications and all-cause mortality 
in Chinese population. This propensity score matched 
cohort study found that RAMP-DM was significantly 
associated with decreases in the risks of all the cardiovas-
cular complications and all-cause mortality. Compared 
to subjects under usual primary care, subjects enrolled in 
RAMP-DM had 37.1 and 63.7 % lower risks of develop-
ing total CVD and all-cause mortality, respectively. Also, 
the RAMP-DM group had a lower incidence of all three 
components of CVD, with adjusted HRs of 0.570 (95 % CI 
0.470 to 0.691, P < 0.001), 0.652 (95 % CI 0.546 to 0.780, 
Fig. 1 Flow chart of subjects matching. RAMP-DM risk assessment and management programme for patients with diabetes mellitus.
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P < 0.001) and 0.598 (95 % CI 0.446 to 0.802, P = 0.001) 
for CHD, stroke and heart failure respectively. The sub-
stantial reduction in the incidence of all-cause mortality 
in RAMP-DM group might be mainly attributed to the 
significant decreases in life-threatening diabetic cardio-
vascular complications.
Sub-group analysis showed that RAMP-DM was asso-
ciated with decreased risks of total CVD, CHD and all-
cause mortality in all three sub-groups. In the sub-group 
of subjects with HbA1c ≥8.5  %, the risks of stroke and 
heart failure were similar between RAMP-DM and con-
trol groups. It is possible that for subjects with higher 
HbA1c, doctors tended to give them more intensive 
intervention, no matter whether they were enrolled in 
RAMP-DM or not, and patients under usual care were 
eligible to be referred to some services in the RAMP-
DM intervention package, like care from allied health 
professionals, which might bias the effects of RAMP-
DM towards null. The relatively small number of sub-
jects (2,257 out of 18,188) in this sub-group might also 
limit the power to detect a significant effect although the 
results favored the RAMP-DM group.
Previously, we reported a pilot study in a sample of 1,072 
pairs of RAMP-DM and control subjects at 12  months 
follow-up [20]. We found that the RAMP-DM group 
showed improvement in surrogate effectiveness measures 
including HbA1c level and predicted cardiovascular risks. 
Although the numbers of observed CVD events were small 
Table 2 Basic characteristics at baseline and 3 years
BMI body mass index, CSSA comprehensive social security assistance, DBP diastolic blood pressure, DM dibetes mellitus, eGFR estimated glomerular filtration rate, 
HbA1c hemoglobin A1c, HDL-C high density lipid cholesterol, LDL-C low density lipid cholesterol, SBP systolic blood pressure and TC total cholesterol.
a Significant differences (P < 0.05) between groups by independent t test or by Chi-square test, as appropriate.
b Add up the comorbidity component score in Charlson comorbidity index.
At baseline At the end of follow‑up
RAMP (N = 9,094) Control (N = 9,094) P valuea RAMP (N = 8,892) Control (N = 8,542) P valuea
Mean ± SD or N (%) Mean ± SD or N (%) Mean ± SD or N (%) Mean ± SD or N (%)
Socio-demographic
 Age (year) 64.23 ± 11.05 64.29 ± 11.96 0.751
 Female 4,713 (51.8 %) 4,774 (52.5 %) 0.365
 On CSSA 1,293 (14.2 %) 1,340 (14.7 %) 0.322
Clinical measures
 Duration of DM (year) 8.31 ± 6.75 8.42 ± 6.15 0.258
 Current smoker 927 (10.2 %) 906 (10.0 %) 0.605 346 (9.0 %) 235 (8.6 %) 0.651
 BMI (kg/m2) 25.33 ± 3.74 25.33 ± 3.90 0.900 25.07 ± 3.79 25.11 ± 3.92 0.540
 SBP (mm Hg) 135.41 ± 17.05 135.45 ± 16.56 0.865 130.12 ± 14.68 132.35 ± 15.51 <0.001
 DBP (mm Hg) 75.11 ± 10.34 75.08 ± 9.77 0.828 71.60 ± 10.26 73.23 ± 9.72 <0.001
 HbA1c (%) 7.24 ± 1.23 7.24 ± 1.24 0.775 7.13 ± 1.09 7.25 ± 1.26 <0.001
 TC (mmol/L) 5.08 ± 0.94 5.08 ± 0.95 0.976 4.43 ± 0.82 4.49 ± 0.86 <0.001
 HDL-C (mmol/L) 1.22 ± 0.32 1.22 ± 0.32 0.504 1.28 ± 0.34 1.31 ± 0.35 <0.001
 LDL-C (mmol/L) 3.13 ± 0.82 3.14 ± 0.83 0.487 2.51 ± 0.69 2.55 ± 0.72 <0.001
 Triglyceride (mmol/L) 1.64 ± 1.10 1.64 ± 1.05 0.923 1.43 ± 0.87 1.43 ± 0.97 0.874
 eGFR (ml/min/1.73 m2) 81.68 ± 20.81 81.68 ± 19.43 0.983 80.88 ± 22.92 81.02 ± 22.51 0.725
 Charlson comorbidity scoreb 0.04 ± 0.26 0.04 ± 0.26 0.651 0.07 ± 0.35 0.08 ± 0.38 0.069
Percentage reaching treatment target
 SBP <130 mmHg 37.61 % 36.83 % 0.276 50.31 % 45.45 % <0.001
 DBP <80 mmHg 66.49 % 67.39 % 0.202 78.39 % 74.45 % <0.001
 HbA1c <7 % 48.37 % 47.36 % 0.172 52.10 % 48.81 % <0.001
 LDL-C <2.6 mmol/L 26.57 % 27.38 % 0.218 59.18 % 58.46 % 0.384
Treatment modality
 On glucose-lowering drugs 7,943 (87.3 %) 7,929 (87.2 %) 0.755 7,999 (90.0 %) 7,143 (83.6 %) <0.001
 On anti-hypertensive drugs 6,637 (73.0 %) 6,673 (73.4 %) 0.547 7,112 (80.0 %) 6,493 (76.0 %) <0.001
 On lipid-lowering drugs 1,189 (13.1 %) 1,225 (13.5 %) 0.431 4,551 (51.2 %) 3,903 (45.7 %) <0.001
 On insulin 105 (1.2 %) 130 (1.4 %) 0.101 534 (6.0 %) 386 (4.5 %) <0.001
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due to a short follow-up period and small sample size, the 
observed CVD event rate in the RAMP-DM group was 
significantly lower (RAMP-DM vs control: 1.21 vs 2.89 %, 
P = 0.003) at 12 months follow-up. The current study con-
firmed the favorable findings for the RAMP-DM group in 
avoidance of cardiovascular complications using a more 
representative sample and a longer follow-up period.
Previous studies on short-term effectiveness of risk-
stratification based intervention were conducted in U.S. 
[25] and U.K. [26]. Both studies reported the increase in 
the percentages of subjects reaching target HbA1c, blood 
pressure in the intervention group. However, long-term 
effectiveness of the intervention on cardiovascular events 
was not reported. In Asia, attempt for the risk stratifica-
tion management was made by the Joint Asia Diabetes 
Evaluation Program (JADE) [27]. Clinicians can access a 
web-based comprehensive risk stratification model using 
an electronic portal. During 2007–2009, 3,687 people 
with diabetes across seven Asian countries, including 
Hong Kong, were enrolled [21]. The implementation of 
the structured care and effectiveness of this care model 
compared to usual care is not clear.
Our study reported the long-term effectiveness of the 
risk-stratification management for patients with DM. We 
observed significant lower incidences of all cardiovas-
cular complications in the RAMP-DM group, whereas 
the between group differences of HbA1c was mod-
est (7.13 ± 1.09 % vs 7.25 ± 1.26 %, P < 0.001) at three-
year follow-up. Although it is reported that an increase 
in HbA1c level is significantly associated with the inci-
dence of coronary heart disease over 6  years follow-up 
[28], intensive blood glucose control centered on drug 
interventions did not necessarily lead to success in pre-
venting future cardiovascular events. The  Preterax and 
Diamicron Modified Release Controlled Evaluation 
(ADVANCE) trial showed that over 5 years of follow-up, 
the intensive control group achieved lower HbA1c than 
the control group (6.5 vs 7.3 %), but it failed to reduce the 
risk all the cardiovascular complications [29]. The inten-
sive glucose control trial in the United Kingdom Prospec-
tive Diabetes Study (UKPDS) found that after 10  years 
follow-up, although the intensive glucose control had 
11  % reduction in HbA1c (7.0 vs 7.9  %), they did not 
observed significant risk reduction in any cardiovascular 
complications [30]. Interestingly, the post-trial 10  years 
follow-up found decreased risks of myocardial infarction 
and all-cause death although the two groups converged 
to similar HbA1c in the follow-up period [31].
These contradictory results encourage exploration 
of alternative approaches to long-term management of 
people with diabetes. The Steno-2 study implemented a 
multifactorial intervention including a combination of 
medications and focused behavior modification. It was 
reported that the intervention group had lower risks of 
cardiovascular events (HR 0.41) over 13.3 years follow-up 
compared to the conventional care group [32]. A physi-
cian-led structured diabetes management program in 
Germany also showed lower incidences of MI (risk ratio 
0.75) and stroke (risk ratio 0.80) among the intervention 
group over 4 years follow-up. This program involved edu-
cation and structured evidence-based care by physicians 
[33].
The remarkable reduction in the incidences of car-
diovascular complications and all-cause mortality in the 
RAMP-DM group might result from several reasons. 
First, structured risk assessment improved adherence 
to recommendation on annual assessment to detect 
reversible risk factors early, e.g. hypertension and hyper-
lipidemia, so that timely interventions could be given 
to prevent further deterioration. Second, significantly 
higher proportions of subjects in the RAMP-DM group 
were treated with glucose-lowering drugs, insulin, anti-
hypertensive drugs and lipid-lowering drugs, which sug-
gested that the doctors might have managed the patients 
more intensively after knowing the risk stratification by 
RAMP-DM. Third, the risk stratification might also have 
positive impact on improving patients’ consciousness of 
Table 3 Number of  diabetic macrovascular complication 
and all-cause death at a median follow-up of 36 months
RAMP-DM multi-disciplinary risk assessment and management-diabetes 
mellitus. CVD cardiovascular disease, CHD coronary heart disease and CI 
confidence interval.
* The 95 % CI was constructed based on Poisson distribution.
Cumulative  
incidence
Incidence rate (cases/100 person‑
years)
No. 
of events
Rate (%) Estimate 95 % CI* Person‑
years
RAMP-DM group (N = 9,094)
 CVD 399 4.39 1.495 (1.352, 1.650) 26,681
 CHD 170 1.87 0.631 (0.540, 0.733) 26,938
 Stroke 205 2.25 0.763 (0.662, 0.874) 26,882
 Heart 
Failure
72 0.79 0.266 (0.208, 0.335) 27,040
 All-cause 
mortal-
ity
202 2.22 0.745 (0.646, 0.856) 27,101
Control group (N = 9,094)
 CVD 608 6.69 2.420 (2.231, 2.620) 25,127
 CHD 280 3.08 1.099 (0.974, 1.235) 25,482
 Stroke 309 3.40 1.216 (1.084, 1.359) 25,418
 Heart 
failure
125 1.37 0.487 (0.405, 0.580) 25,660
 All-cause 
mortal-
ity
552 6.07 2.144 (1.968, 2.330) 25,752
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health and motivating them to change lifestyles. Physical 
activity was found to decrease the risk of cardiovascu-
lar morality in DM patients [34]. Fourth, the multidisci-
plinary RAMP-DM team provided more education, e.g. 
the smoking cessation, about complications preven-
tion, providing patients with additional treatment. Fifth, 
RAMP-DM also led to significant decreases in HbA1c, 
blood pressure and LDL-C compared to the control 
group, which could all lower the complication risks. 
These changes could all contributed to the impressive 
effectiveness of the RAMP-DM intervention, which was 
consistent with the remarkable findings of multifactorial 
Fig. 2 Kaplan-Meier survival curves. CVD cardiovascular diseases and CHD coronary heart disease.
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Steno-2 study [32] and the multidisciplinary care in Ger-
many [33]. However, longer term follow-up is required 
to valid the effectiveness of RAMP-DM over a longer 
time-span.
Strength and limitations of this study
This population-based prospective comparative effec-
tiveness study had several strengths. First, we sampled 
the study subjects from the Clinical Management Sys-
tem of the Hospital Authority, which recorded data on all 
the people with diabetes managed in the public health-
care sector. This population-based sample was highly 
representative of the Hong Kong population with dia-
betes. Second, we included comprehensive covariates to 
develop propensity score matching for the two groups. 
The observed risk factors that might affect the incidence 
of diabetic cardiovascular complications were included. 
The two groups were well matched at baseline and we 
further adjusted all the covariates during multivariable 
Cox regression to minimize any possible bias. Third, we 
conducted this comparative effectiveness study using pri-
mary care data, providing evidence, if real, can be applied 
in a real-world setting. Fourth, we used an intention-to-
treat analysis, giving a more conservative estimate of the 
effectiveness of RAMP-DM.
An important limitation of this study is that we could 
not carry out a randomized study therefore unobserved 
potential confounders might affect the results, although 
we have minimised this as much as we can. Second, the 
control subjects in our study were selected from those 
who were either had not been introduced to the RAMP-
DM or refused to join the program. There was a possi-
bility that the control subjects were less health conscious 
than the RAMP-DM subjects, which could partly con-
tribute to their worse outcomes. Third, not all the RAMP-
DM subjects were included in the analysis due to missing 
data at baseline and some subjects were further excluded 
due to unavailable matched control pairs. Fourth, we 
identified the occurrence of cardiovascular complications 
by clinical diagnosis codes. There was a possibility of 
under-diagnoses or coding misclassification errors. Fifth, 
3  years are not long enough to project the longer term 
benefits of RAMP-DM. We will continue to observe the 
effects of RAMP-DM over a longer time-span.
Conclusion
This prospective comparative effectiveness study in a 
pragmatic primary care setting found that RAMP-DM 
was associated with decreased incidences of total CVD, 
CHD, stroke, heart failure, and all-cause mortality among 
diabetic subjects without pre-existing complications over 
3  years of follow-up. These findings provide imperative 
translational evidence of the effectiveness of multidisci-
plinary risk-stratification based management for Chinese 
people with DM. Further study on the longer term effects 
of RAMP-DM in preventing diabetic cardiovascular 
complications will be conducted with a longer follow-up 
period.
Additional file
Additional file 1: Figure S1. The patient management flowchart 
of RAMP-DM. Legends: APN, Advanced Practice Nurse; AC, Associate 
consultant.
Table 4 Multivariable Cox proportional hazard regression 
in all endpoints
Adjusted for the socio-demographic and clinical characteristics.
AIC Akaike information criterion, BIC Bayesian information criterion, CHD 
coronary heart disease, CVD cardiovascular disease, HR hazard ratio, SE standard 
error and HbA1c hemoglobin A1c.
† HR >1 indicates greater risk for endpoints.
RAMP‑DM vs Control Harrell’s 
C‑statistic
HR† SE 95 % CI P value
RAMP-DM subjects vs control subjects (all subjects, N = 18,188)
 CVD 0.629 0.041 (0.554, 0.715) <0.001 0.75 (0.73,0.76)
 CHD 0.570 0.056 (0.470, 0.691) <0.001 0.74 (0.72,0.76)
 Stroke 0.652 0.059 (0.546, 0.780) <0.001 0.76 (0.74,0.78)
 Heart failure 0.598 0.090 (0.446, 0.802) 0.001 0.87 (0.85,0.90)
 All-cause 
mortality
0.363 0.030 (0.308, 0.428) <0.001 0.82 (0.80,0.83)
RAMP-DM subjects vs control subjects (baseline HbA1c <7 %, N = 8,540)
 CVD 0.592 0.055 (0.494, 0.711) <0.001 0.74 (0.72,0.76)
 CHD 0.553 0.075 (0.423, 0.722) <0.001 0.75 (0.71,0.78)
 Stroke 0.553 0.075 (0.425, 0.720) <0.001 0.75 (0.72,0.78)
 Heart failure 0.680 0.136 (0.459, 1.006) 0.054 0.88 (0.85,0.91)
 All-cause 
mortality
0.415 0.046 (0.335, 0.515) <0.001 0.81 (0.79,0.83)
RAMP-DM subjects vs control subjects (baseline HbA1c 7–8.5 %, 
N = 7,047)
 CVD 0.703 0.074 (0.572, 0.864) 0.001 0.75 (0.73,0.77)
 CHD 0.650 0.108 (0.470, 0.899) 0.009 0.75 (0.71,0.79)
 Stroke 0.779 0.111 (0.590, 1.029) 0.079 0.77 (0.74,0.80)
 Heart failure 0.455 0.124 (0.267, 0.776) 0.004 0.88 (0.84,0.92)
 All-cause 
mortality
0.292 0.043 (0.219, 0.389) <0.001 0.83 (0.80,0.85)
RAMP-DM subjects vs control subjects (baseline HbA1c ≥8.5 %, 
N = 2,257)
 CVD 0.576 0.109 (0.397, 0.836) 0.004 0.79 (0.75,0.83)
 CHD 0.450 0.132 (0.254, 0.799) 0.006 0.75 (0.68,0.81)
 Stroke 0.624 0.164 (0.373, 1.043) 0.072 0.85 (0.81,0.88)
 Heart failure 0.664 0.294 (0.279, 1.581) 0.355 0.86 (0.78,0.94)
 All-cause 
mortality
0.303 0.085 (0.175, 0.525) <0.001 0.84 (0.79,0.88)
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